ETF profile for Roundhill Glp-1 & Weight Loss ETF (OZEM) from the issuer: top holdings, net assets, expense ratio and shares outstanding.
OZEM ETF Profile
| Family: |
Roundhill Financial |
| Name: |
Roundhill GLP-1 & Weight Loss ETF |
|
|
| Inception Date: |
21-May-2024 |
| Termination Date: |
|
| Investment Objective: |
The Fund is an actively managed exchange-traded fund ("ETF") that pursues its investment objective by seeking to provide exposure to companies involved in the development of pharmaceutical drugs and/or supplements that can be utilized to help individuals lose weight, maintain an ideal weight, and/or maintain body composition during weight loss ("GLP-1 & Weight Loss Drugs"). The Fund will focus its investments in the securities of companies that are the acknowledged leaders in the development of GLP-1 & Weight Loss Drugs, which it defines as those companies that have GLP-1 & Weight Loss Drugs currently undergoing Phase I, Phase II, and/or Phase III of U.S. Food & Drug Administration ("FDA") clinical trials and in securities of companies with GLP-1 & Weight Loss Drugs that have been approved by the FDA ("GLP-1 & Weight Loss Companies"). The Fund will also only invest in those companies with a minimum market capitalization of 100 million and an average daily trading volume of 500,000. The Adviser rebalances the weighting of the companies comprising the Fund's portfolio on at least a quarterly basis. The Fund may invest in U.S. and non-U.S. companies (including through investments in depositary receipts) and small-, mid- and large-capitalization issuers. |
|
|
| Prospectus |
|
|
|
| Top 10 Holdings |
|
|
| Eli Lilly & Co |
LLY |
15.7200% |
| Novo Nordisk A/S |
NVO |
11.9600% |
| Pfizer Inc |
PFE |
8.2200% |
| Kailera Therapeutics Inc |
KLRA |
5.7900% |
| CSPC Pharmaceutical Group Ltd |
1093 |
5.1800% |
| Chugai Pharmaceutical Co Ltd |
4519 |
5.1400% |
| Amgen Inc |
AMGN |
4.8600% |
| Viking Therapeutics Inc |
VKTX |
4.4500% |
| AstraZeneca PLC |
AZN |
4.3800% |
| Hanmi Pharm Co Ltd |
128940 |
3.6800% |
|
Top 10 Holdings Weight: |
69.4% |
| Number of Holdings: |
25 |
| Shares Outstanding: |
1,830,000 |
| Total Net Assets: |
55,368,480 |
| NAV: |
30.33 |
| Net Expense Ratio: |
0.59% |
|
|
| Asset Class: |
Equities (Stocks) |
| Developed or Emerging: |
Developed Market Funds |
| Country: |
|
| Region: |
|
| Strategy: |
|
| Currency: |
|
| Commodity: |
|
| Sector: |
Healthcare |
| Industry: |
Pharmaceuticals |
| Dividend Type: |
|
| Tax Exempt State: |
|
| Maturity Duration: |
|
| Market Cap: |
Broad Market / Multi-Cap |
| Credit Quality: |
|
| Mortgage Bond Types: |
|
| Bond Type: |
|
| Gov't Bond Types: |
|
| Reit Type: |
|
| Leverage Direction/Factor: |
|
| Is Currency Hedged: |
No |
| US or Ex-US: |
Global |
